Lenalidomide

From Ganfyd

Jump to: navigation, search

Contents

Introduction

Used in treatment of multiple myeloma. Similar to thalidomide, but with more favorable side-effect profile.[1] The main barrier to increased use is its cost premium over thalidomide..

Clinical Use

Indications

  • Multiple myeloma
  • Note: EU license for anaemia caused by myelodysplastic syndromes associated with deletion of 5q, refused June 2008. Was approved in Switzerland in November 2011 for anaemia caused by low-or intermediate-1-risk myelodysplastic syndromes.

Administration

Oral

Clinical Issues

LogoKeyPointsBox.pngIn a wide range of multiple myeloma indications lenalidomide:
  • Increases markedly progression free survival
  • Has no impact on overall survival

Contra-indications

Cautions and Interactions

Side effects

  • Risk of VTE
  • Associated with increased incidence of secondary cancer

Special advice

Pharmacology

A tumour necrosis factor alpha (TNF-α) inhibitor.


References

Personal tools